Icon awarded FDA project to validate PRO instruments

By Melissa Fassbender

- Last updated on GMT

Icon awarded FDA project to validate PRO instruments

Related tags Contract research organization

The US Food & Drug Administration (FDA) has tasked Icon plc to validate three patient-reported outcomes (PRO) instruments in antibacterial drug trials.

Icon’s Clinical Outcomes Assessment (COA) group and the Biomarkers Consortium of the Foundation for the National Institutes of Health (FNIH) will collaborate on an electronic platform to validate the PROs – allowing investigators to evaluate symptoms and measure the effects of antibacterial drugs.

According to the contract research organization (CRO), the specific conditions in which the endpoints will be validated, include Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Community-Acquired Bacterial Pneumonia (CABP), and Hospital-Acquired Bacterial Pneumonia (HABP).

Through the trials, patients will use a handheld device​ with PROs to be implemented on CRF Health’s TrialMax® eCOA platform.

These PROs will continue to be validated and developed in accordance with the FDA guidance for PRO measures used to support labeling claims and will follow the Drug Development Tool (DDT) Qualification Program​,” the company said.

The FDA previously selected​ Icon to develop new PRO instruments in November 2014.

(Feature image: iStock/zozzzzo)

Related news

Show more

Related products

show more

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us

Products

View more

Webinars